IUdR polymers for combined continuous low-dose rate and high-dose rate sensitization of experimental human malignant gliomas

Evaluation of the combined effect of NIR laser and ionizing radiation on cellular damages induced by IUdR-loaded PLGA-coated Nano-graphene oxide

Glioma is one of the most common malignant cancers of the central nervous system (CNS). Radiatherapy and chemotherapy may be used to slow the growth of tumors that cannot be removed with surgery. The current study developed a combination therapy tool using Nanographene oxide (NGO) functionalized with poly lactic-co-glycolic acid (PLGA) as a carrier of 5-iodo-2-deoxyuridine (IUdR) for glioma cancer treatment. U87MG cells were treated in different groups with IUdR, PLGA-coated Nanographene oxide (PLGA-NGO), IUdR-loaded PLGA-coated Nanographene oxide (IUdR-PLGA-NGO), 2Gy 6MV X-ray radiation, and near-infrared region (NIR) laser radiation. PLGA-NGO showed excellent biocompatibility, high storage capacity for IUdR and high photothermal conversion efficiency. It was effectively employed to create cell damage in the U87MG cell line in the presence of X-ray (6 MV) and NIR laser. Moreover, IUdR-PLGA-NGO+X-ray+NIR laser significantly reduced the plating efficiency of the cells in comparison with IUdR-PLGA-NGO+X-ray and IUdR-PLGA-NGO+NIR laser. Furthermore, Prussian blue staining showed that IUdR-PLGA-NGO-SPIONs were delivered into glioblastoma cells. The PLGA-NGO loaded with IUdR under NIR and X-ray radiation exhibited the highest cytotoxicity toward U87MG cells when compared with other treatment methods, indicating efficient radio-photothermal targeted therapy.

Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation

PURPOSE

We compared clonogenic survival in 27 human tumor cell lines that vary in genotype after low-dose-rate (LDR) or high-dose rate (HDR) irradiation. We measured susceptibility to LDR-induced redistribution in the cell cycle in eight of these cell lines.

METHODS AND MATERIALS

We measured clonogenic survival after up to 96 hours of LDR (0.25 Gy/h) irradiation. We compared these with clonogenic survival after HDR irradiation (50 Gy/h). Using flow cytometry, we measured LDR-induced redistribution as a function of time during LDR irradiation in eight of these cell lines.

RESULTS

Coefficients that describe clonogenic survival after both LDR and HDR irradiation segregate into four radiosensitivity groups that associate with cell genotype: mutant (mut)ATM, wild-type TP53, mutTP53, and an unidentified gene in radioresistant glioma cells. The LDR and HDR radiosensitivity correlates at lower doses ( approximately 2 Gy HDR, approximately 6 Gy LDR), but not at higher doses (HDR > 4 Gy; LDR > 6 Gy). The rate of LDR-induced loss of clonogenic survival changes at approximately 24 hours; wild-type TP53 cells become more resistant and mutTP53 cells become more sensitive. Redistribution induced by LDR irradiation also changes at approximately 24 hours.

CONCLUSIONS

Radiosensitivity of human tumor cells to both LDR and HDR irradiation is genotype dependent. Analysis of coefficients that describe cellular radiosensitivity segregates 27 cell lines into four statistically distinct groups, each associating with specific genotypes. Changes in cellular radiosensitivity and redistribution in the cell cycle are strongly time dependent. Our data establish a genotype-dependent time-dependent model that predicts clonogenic survival, explains the inverse dose-rate effect, and suggests possible clinical applications.

Barriers to carrier mediated drug and gene delivery to brain tumors

Brain tumor patients face a poor prognosis despite significant advances in tumor imaging, neurosurgery and radiation therapy. Potent chemotherapeutic drugs fail when used to treat brain tumors because biochemical and physiological barriers limit drug delivery into the brain. In the past decade a number of strategies have been introduced to increase drug delivery into the brain parenchyma. In particular, direct drug administration into the brain tumor has shown promising results in both animal models and clinical trials. This technique is well suited for the delivery of liposome and polymer drug carriers, which have the potential to provide a sustained level of drug and to reach cellular targets with improved specificity. We will discuss the current approaches that have been used to increase drug delivery into the brain parenchyma in the context of fluid and solute transport into, through and from the brain, with a focus on liposome and polymer drug carriers.

Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice

To study the optimum therapeutic modalities for treating human malignant brain tumors in vivo without ethical limitations, a model of heterotopic and another of orthotopic xenografting into nude mice were developed. For the first implantation, 11 human high-grade gliomas and 4 low-grade tumors were microsurgically grafted on epigastric vessels. The 11 high-grade gliomas, but no low-grade tumors, were established into nude mice. Afterwards, all these mouse-adapted gliomas which grafted into other nude mice developed. Introduction of a microcatheter into the femoral artery or vein permitted infusion for magnetic resonance imaging (MRI) and treatment. A bladder catheter setting and electrode implantation allowed urine sampling and ECG or EEG recording. Thus, the most important parameters of chemo- and radiotherapy to destroy a maximum number of malignant cells or to inhibit their divisions and the hosts reactions to treatment can be studied. The human gliomas transplanted onto the mouse brain infiltrated the host brain at great distances from the tumor, as in human patients. So, this second implantation constitutes a representative model of the evolution of human gliomas, and allows the study of malignant cell migration in the brain before, during and after treatment determined with the heterotopic model and to appreciate the tolerance of the colonized brain to these treatments. Echography and MRI allowed us to follow the macroscopic evolution with or without treatment of the malignant brain tumors transplanted onto mouse brains. It should now be possible to undertake the same clinical studies on patients after appropriate consideration of ethical and scientific constraints.

Effect of gamma-irradiation on cladribine and cladribine-containing biodegradable copolymers

The aims of this study were to assess the effects of sterilization with gamma-irradiation on (i). bulk cladribine and (ii). cladribine-containing biodegradable copolymers. The stability of cladribine upon irradiation was confirmed by TLC, HPLC, UV, IR, DSC, rentgenography and electron microscopy. The stability of copolymers containing cladribine upon irradiation was assessed by IR, DSC and EPR. In vitro kinetics of nucleoside release from the copolymers before and after irradiation were compared, and only slight changes were found. Results of our study indicate that gamma-irradiation can be safely applied for the sterilization of cladribine or cladribine-containing copolymers for medical purposes.